LexaGene Provides Corporate Update

March 11, 2020

BEVERLY, Mass. – March 11, 2020 – LexaGene Holdings, Inc., (OTCQB: LXXGFTSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, provides the following corporate update on the development of its commercial technology and information on how the Company has responded to the demand for its technology in view of the COVID-19 outbreak.

In response to the COVID-19 outbreak, the World Health Organization has declared a ‘Public Health Emergency of International Concern’ and the FDA has encouraged CLIA labs and IVD manufacturers to submit applications for Emergency Use Authorization (EUA) to help address the lack of quality diagnostics to fight this disease.  The FDA’s track record of granting EUA during declared emergencies, such as the Ebola and Zika outbreaks, provides management confidence that the Company’s decision to pursue EUA is in the best interest of its shareholders, its future customers and the patients they serve.  Due to the overwhelming interest in LexaGene’s rapid, on-site analyzer for the detection of novel infectious diseases like COVID-19, LexaGene is taking every measure to accelerate its FDA EUA submission.

To read the full article, please visit https://lexagene.com/release/2020/lexagene-provides-corporate-update-2/